News

Your treatment room lights could be weakening your methylcobalamin before it ever reaches the patient, and the vial will still look perfectly normal. Learn why ordinary room light breaks down B12 and the three simple habits that make sure every patient gets the full dose you prescribed.

Six peptides, including BPC-157, can now be compounded by 503A pharmacies, but only if every strict condition is met. HHS's new policy is temporary, it isn't FDA approval, and it doesn't cover 503B outsourcing facilities. Here's what changed, what didn't, and six questions to ask any pharmacy before you order.

The Food and Drug Administration (FDA) has drafted a temporary policy that may allow pharmacies to compound certain peptides. It’s under White House review. Nobody outside government has seen it, and nothing has changed yet. Whether you’re a patient, a nurse or a physician, here’s what’s known and what isn’t.

On July 23–24, 2026, FDA's Pharmacy Compounding Advisory Committee recommended six peptides for the 503A bulks list: BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax. It voted against Emideltide (DSIP). The recommendation is advice to FDA, not a final decision, so these peptides still can't be legally compounded, and the vote doesn't apply to 503B outsourcing facilities. Here's what the vote means for your practice and what FDA has to do next.

The FDA recently reminded compounders about the risks of using dietary supplement-grade glutathione in injectable preparations. Learn how McGuff Outsourcing Solutions approaches API sourcing, bacterial endotoxin testing, and quality controls for Glutathione Injection.

Review our latest update from McGuff Outsourcing Solutions on our 503B outsourcing facility and product availability. We anticipate a June 2026 product launch and look forward to doing business with healthcare practitioners nationwide.